Evidence map›Paper›PMID 19508169›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2009

Hepatitis C virus infection and the risk of coronary disease.

Adeel A Butt, Wang Xiaoqiang, Matthew Budoff, David Leaf, Lewis H Kuller, Amy C Justice

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 137 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02660905 phase3completednot on this mapstarted 2016, after this paper: background citation

Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal

TypeinterventionalSponsorOttawa Hospital Research InstituteRan2016 to 2018Enrolled25ConditionsHuman Immunodeficiency Virus, Hepatitis C, ChronicArmsE/C/F/TAF, Ledipasvir-Sofosbuvir
NCT03402334 nacompletednot on this mapstarted 2019, after this paper: background citation

Assessing Healthcare Outcomes of Hepatitis C Virus (HCV) Positive Patients Counseled for Cardiovascular Disease Risk Factors

TypeinterventionalSponsorTulane UniversityRan2019 to 2021Enrolled231ConditionsHepatitis C, AtherosclerosisArmsPatient counseling for HCV associated CVD risk factors
3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. La Tunisie medicale · 2024
    Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adeel A ButtVA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Center for Health Equity Research and Promotion, Pittsburgh, Pennsylvania, USA. butta@dom.pitt.edu
Wang Xiaoqiang
Matthew Budoff
David Leaf
Lewis H Kuller
Amy C Justice

Funding

Alcohol Associated Outcomes Among HIV+/- Aging VeteransU10AA013566 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2006 to 2010
$12.7M
Treatment Disparities/Outcomes of HCV-HIV Co-InfectionK23DA016175 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUTT, ADEEL A · 2003 to 2007
$628k
NIAAA NIH HHS U10 AA013566NIDA NIH HHS K23 DA016175NIDA NIH HHS K23 DA016175-01A1
6 · The paper itself

Abstract

backgroundThe association between hepatitis C virus (HCV) infection and coronary artery disease (CAD) is controversial. We conducted this study to determine and quantify this association.

methodsWe used an established, national, observational cohort of all HCV-infected veterans receiving care at all Veterans Affairs facilities, the Electronically Retrieved Cohort of HCV Infected Veterans, to identify HCV-infected subjects and HCV-uninfected control subjects. We used the Cox proportional-hazards model to determine the risk of CAD among HCV-infected subjects and control subjects.

resultsWe identified 82,083 HCV-infected and 89,582 HCV-uninfected subjects. HCV-infected subjects were less likely to have hypertension, hyperlipidemia, and diabetes but were more likely to abuse alcohol and drugs and to have renal failure and anemia. HCV-infected subjects had lower mean (+/- standard deviation) total plasma cholesterol (175 +/- 40.8 mg/dL vs. 198 +/- 41.0 mg/dL), low-density lipoprotein cholesterol (102 +/- 36.8 mg/dL vs. 119 +/- 38.2 mg/dL), and triglyceride (144 +/- 119 mg/dL vs. 179 +/- 151 mg/dL) levels, compared with HCV-uninfected subjects (P < .001 for all comparisons). In multivariable analysis, HCV infection was associated with a higher risk of CAD (hazard ratio, 1.25; 95% confidence interval, 1.20-1.30). Traditional risk factors (age, hypertension, chronic obstructive pulmonary disease, diabetes, and hyperlipidemia) were associated with a higher risk of CAD in both groups, whereas minority race and female sex were associated with a lower risk of CAD.

conclusionsHCV-infected persons are younger and have lower lipid levels and a lower prevalence of hypertension. Despite a favorable risk profile, HCV infection is associated with a higher risk of CAD after adjustment for traditional risk factors.

Indexed as

Risk AssessmentAdultCoronary DiseaseFemaleHepatitis CHumansMaleMiddle AgedRisk FactorsVeterans

Identifiers

PMID19508169
PMCPMC3077953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.